Le Lézard
Classified in: Health
Subjects: PLW, SBS

Kinetic River Corp. Receives First Japanese Patent for Time-Resolved Flow Cytometry


MOUNTAIN VIEW, Calif., Oct. 1, 2021 /PRNewswire/ -- Kinetic River Corp., a leader in custom flow cytometry instrumentation, announced today having been issued a patent from the Japanese Patent Office covering its innovative technologies for time-resolved flow cytometry. The official patent registration number is JP 6941053 B2, issued on September 7, 2021. This patent adds to a portfolio of 12 issued and 17 pending U.S. and international patents.

Flow cytometry is a powerful cell analysis tool with broad utility in research and clinical fields as diverse and important as tumor biology research, cancer and AIDS diagnostics, immunophenotyping, and cancer immunotherapy. Flow cytometry relies heavily on adding fluorescent labels to cells. The drive for simultaneous measurements of more and more such labels, the better to characterize cells in a sample, has been hitting both technological and operational barriers. Spectral crosstalk, due to the broad emission spectra of most common dyes used as labels, forces users to perform burdensome and costly compensation protocols. It also limits the number of dyes that can be measured simultaneously. Related constraints, such as autofluorescence background, limit the sensitivity of current assays.

The subject of Kinetic River's latest issued patent, time-resolved flow cytometry, provides solutions to these longstanding problems. This technology suite provides the ability to measure the lifetime of fluorescence emission following excitation with short laser pulses. This added parameter, in turn, allows discrimination of different dyes not only based on their color but also based on their temporal emission signature.

In one application, Kinetic River's technology enables compensation-free flow cytometry, greatly reducing both the labor burden on users and operators and the operating costs, due to the reduced number of control materials required to perform each experiment. In another application, the technology makes possible fluorescence-based instrumentation capable of measuring simultaneously 40+ colors with high sensitivity.

The patented innovation also allows for automated removal of autofluorescence background in signals from cells or microspheres. By distinguishing autofluorescence from fluorescence due to added dyes, Kinetic River's technology offers greater sensitivity, more robust operation, and reduced operational costs. In addition, the technology demonstrated the ability to characterize autofluorescence emissions, which can be used to distinguish cancer cells from normal ones.

"We are very excited about the Japanese Patent Office's decision," said Giacomo Vacca, Ph.D., president of Kinetic River. "This issuance is the first outside the U.S. for this patent family, and we expect it will be far from the last. We continue to aggressively pursue protection for our extensive intellectual property in a global range of jurisdictions."

By establishing patent protection for this technology suite in Japan, this patent allows Kinetic River to pursue a sizable, growing market with presence across all the major flow cytometry segments.

About Kinetic River
Kinetic River Corp. is a product design and development company focused on flow cytometry and optics. Based in California's Silicon Valley, Kinetic River offers cutting-edge instrumentation solutions for biomedical research and the life sciences, including the Potomac modular flow cytometer and the Danube, a fluorescence lifetime flow cytometer. Kinetic River also provides a range of technical consulting services and training seminars to clients worldwide. For more information, visit KineticRiver.com.

Research reported in this release was supported in part by NIGMS of the U.S. National Institutes of Health under grant numbers 1R43GM131619-01 Revised, 1R43GM128546-01, 1R43GM123906-01, and 2R44GM123906-02A1. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Kinetic River® and the Kinetic River logo are registered trademarks of Kinetic River Corp.

Media Contact:
Giacomo Vacca
(650) 439-7413
[email protected]

SOURCE Kinetic River Corp.


These press releases may also interest you

at 07:35
Endeavor BioMedicines, Inc. ("Endeavor"), a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, today announced the closing of a $132.5...

at 07:30
BioArctic AB's (publ) partner Eisai today published the preliminary global revenue for Leqembi during the first quarter 2024, in conjunction with their partner Biogen's first quarter report. In total, sales of JPY 2.83 billion were recorded in the...

at 07:25
RxLightning, creator of the industry's leading platform for streamlining specialty medication access and affordability, is proud to have reached a number of meaningful milestones in the last year ? including significant increases in provider users,...

at 07:12
Highlights from Chiesi Group's 2023 financial report: Sales increased to over ?3 billion, up 10% compared to 2022 (+12% @CER), driven by the Rare business unit growth (65% @CER), and steady growth of all products in all its Regions24% of 2023 sales...

at 07:05
Av?sis and Harmony Health have joined forces to bridge oral healthcare gaps for underserved Medicaid populations with special healthcare needs. The pilot aims to revolutionize preventive dentistry by harnessing the power of real-time salivary testing...

at 07:05
United Therapeutics Corporation , announced today that it will report its first quarter 2024 financial results before the market opens on Wednesday, May 1, 2024. A press release detailing the quarterly results will be issued that day at approximately...



News published on and distributed by: